Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07944638

Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants

Sponsor: Göteborg University

View on ClinicalTrials.gov

Summary

Babies born extremely preterm (before 28 weeks of pregnancy) miss most of the transfer of two long-chain fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), that normally passes from mother to baby in the last three months of pregnancy. Low levels of these fatty acids after birth have been linked to retinopathy of prematurity (ROP), an eye disease that can threaten vision, and to other complications of prematurity. In a Swedish randomized trial (Mega Donna Mega), an enteral supplement of ARA and DHA reduced severe ROP by about half. A similar supplement, NeoMega36, is now used in routine care in several European neonatal units and is being introduced in Sweden. This observational study examines whether the introduction of NeoMega36 into routine care is followed by less ROP and fewer other complications of prematurity. It compares infants born at 22+0 to 27+6 weeks of gestation who were cared for before NeoMega36 was introduced at their unit (historical period) with infants cared for after it was introduced (NeoMega period). The study has two parts: * European part: participating neonatal units report aggregated counts (number of infants and number with each outcome, by gestational week and period). No individual-level data leave the hospitals. * Swedish part: coded individual-level data are retrieved from the Swedish Neonatal Quality Register (SNQ) and the Swedish national register for ROP (SWEDROP). The study does not give, assign or change any treatment. NeoMega36 is given as part of routine clinical care according to each unit's own practice. There are no extra examinations, visits or contacts with families. The main hypothesis is that the proportion of infants with severe ROP is lower in the NeoMega period than in the historical period. Other outcomes are treated ROP, any ROP, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), death before discharge, and the combined outcomes BPD or death and NEC or death. Because this is a before-and-after comparison, differences between the periods may also reflect other changes in care over time, and the results will be interpreted with this in mind.

Official title: Multinational Observational Before-and-after Study of Clinical Outcomes After Introduction of NeoMega36 Fatty-acid Supplementation in Extremely Preterm Infants

Key Details

Gender

All

Age Range

Any - 28 Days

Study Type

OBSERVATIONAL

Enrollment

2100

Start Date

2026-06-16

Completion Date

2036-03-31

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Enteral arachidonic acid and docosahexaenoic acid supplement

Enteral lipid supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) in a 2:1 ratio (NeoMega36, Neobiomics, Solna, Sweden), given in routine neonatal care according to each unit's local protocol for eligibility, dose, and start and stop criteria. The supplement is not assigned, provided or changed by the study. Exposure is defined at period level as implementation of NeoMega36 in routine care at the unit.

Locations (1)

Sahlgrenska Academy, University of Gothenburg

Gothenburg, Sweden